Vesiculobullous Skin Diseases: Pemphigus Vulgaris vs. Bullous Pemphigoid
Table of Contents
Vesiculobullous skin diseases are a group of autoimmune disorders characterized by blister formation on the skin and mucous membranes. Pemphigus vulgaris and bullous pemphigoid are two of the most well-known types of these disorders, each with unique characteristics, causes, and treatment approaches. While they share some similarities, understanding the differences between these conditions is crucial for accurate diagnosis, effective treatment, and improved patient outcomes (Ahmed & Sinha, 2017).
Vesiculobullous Skin Diseases: Pemphigus Vulgaris vs. Bullous Pemphigoid
Overview of Vesiculobullous Skin Diseases
Vesiculobullous skin diseases involve the formation of vesicles (small blisters) or bullae (larger blisters) due to immune responses targeting the structural proteins that maintain skin integrity. In autoimmune vesiculobullous diseases, the body’s immune system mistakenly attacks proteins responsible for skin cohesion, resulting in the separation of skin layers and subsequent blistering (Amagai, 2017).
- Pemphigus Vulgaris (PV): An autoimmune disease characterized by blister formation within the epidermal layer of the skin.
- Bullous Pemphigoid (BP): An autoimmune disorder with blister formation between the epidermis and dermis, creating a more robust and less fragile blister.
Pemphigus Vulgaris
Pemphigus vulgaris (PV) is a rare autoimmune disease in which the immune system attacks specific proteins in the epidermis, leading to painful, fragile blisters on the skin and mucous membranes (Scully & Challacombe, 2002).
Causes and Mechanism
In PV, the immune system produces autoantibodies that target desmoglein-1 and desmoglein-3, proteins found in desmosomes, which are responsible for cell adhesion within the epidermis.
- Autoimmune Target: The autoantibodies attack desmogleins, disrupting cell-to-cell adhesion in the epidermal layer.
- Blister Formation: This disruption leads to acantholysis, or the separation of epidermal cells, causing intraepidermal blistering. The blisters are fragile and easily rupture, leading to painful erosions and lesions (Ahmed & Sinha, 2017).
Symptoms of Pemphigus Vulgaris
- Blisters on Skin and Mucous Membranes: PV often begins with blisters in the mouth, which may later spread to the skin, particularly on the scalp, face, chest, and back.
- Painful Erosions: The blisters are typically painful, and because they are so fragile, they easily break, leaving raw, open areas susceptible to infection.
- Nikolsky Sign: A clinical sign where gentle pressure on normal-appearing skin causes the outer layer to separate, indicating the fragility of the skin.
Diagnosis of Pemphigus Vulgaris
- Skin Biopsy and Immunofluorescence: A skin biopsy is commonly used to confirm PV, with direct immunofluorescence showing IgG antibodies attached to desmosomal proteins.
- Blood Tests for Autoantibodies: Blood tests can identify circulating autoantibodies against desmogleins, supporting the diagnosis.
Bullous Pemphigoid
Bullous pemphigoid (BP) is an autoimmune disorder that primarily affects older adults. It is characterized by the formation of large, tense blisters, usually on the skin, and is typically less severe than pemphigus vulgaris (Schmidt & Zillikens, 2013).
Causes and Mechanism
In BP, the immune system produces autoantibodies against BP180 and BP230, two proteins in hemidesmosomes, which are responsible for anchoring the epidermis to the underlying dermis.
- Autoimmune Target: The antibodies in BP target hemidesmosomal proteins, disrupting the connection between the epidermis and dermis.
- Blister Formation: This disruption leads to a subepidermal separation, creating a more resilient blister that is less prone to rupture compared to those in PV (Amagai, 2017).
Symptoms of Bullous Pemphigoid
- Tense, Itchy Blisters: BP usually presents with large, tense blisters on areas like the abdomen, inner thighs, and forearms. The blisters are less fragile than those in PV and are often itchy rather than painful.
- Skin Redness and Swelling: The skin around the blisters may appear red and swollen, and the blisters may contain clear or yellowish fluid.
- Less Likely to Involve Mucous Membranes: Unlike PV, BP rarely affects mucous membranes like the mouth or eyes.
Diagnosis of Bullous Pemphigoid
- Skin Biopsy and Immunofluorescence: A biopsy will show subepidermal blisters, and direct immunofluorescence will detect IgG and C3 deposits at the basement membrane.
- Blood Tests for Autoantibodies: Testing for autoantibodies against BP180 and BP230 proteins in the blood supports a BP diagnosis.
Key Differences Between Pemphigus Vulgaris and Bullous Pemphigoid
| Feature | Pemphigus Vulgaris (PV) | Bullous Pemphigoid (BP) |
|---|---|---|
| Location of Blisters | Intraepidermal (within the epidermis) | Subepidermal (between epidermis and dermis) |
| Autoantibody Target | Desmoglein-1 and Desmoglein-3 | BP180 and BP230 |
| Blister Characteristics | Fragile, easily ruptured | Tense, more resilient |
| Pain vs. Itch | Painful, especially in mucous membrane blisters | Itchy rather than painful |
| Mucous Membrane Involvement | Common, especially in the mouth | Rare |
| Age of Onset | Often younger adults | Primarily affects older adults |
Treatment Approaches for Pemphigus Vulgaris and Bullous Pemphigoid
Treatment of vesiculobullous diseases like PV and BP aims to reduce immune system activity, control symptoms, and prevent complications. While conventional treatments are essential, integrating Ayurvedic approaches may provide additional support for long-term management.
Conventional Treatment
- Corticosteroids: High-dose corticosteroids are commonly used to reduce inflammation and immune response in both PV and BP.
- Immunosuppressants: Drugs like azathioprine, mycophenolate mofetil, or methotrexate may be prescribed to suppress the immune system and decrease antibody production (Schmidt & Zillikens, 2013).
- Biologic Therapies: Rituximab, a monoclonal antibody, has shown effectiveness in reducing B-cell activity in PV, providing relief for some patients.
- Antibiotics and Antiseptics: To prevent infections in open blisters, topical antibiotics and antiseptics may be used.
Ayurvedic Approach to Support Skin Health and Immune Balance
Ayurveda offers a holistic approach that can complement conventional treatments by focusing on immune balance, reducing inflammation, and supporting skin health.
- Dietary Adjustments
- Pitta-Pacifying Diet: Since PV and BP often involve inflammation, a Pitta-balancing diet can help cool the system and reduce flare-ups. Foods like cucumbers, leafy greens, and coconut water are recommended, while spicy, fried, and acidic foods are minimized (Tiwari, 2001).
- Vata-Balancing Foods: For patients with skin dryness or cracking, warm, nourishing foods that support hydration and grounding are advised.
- Detoxification and Immune Support
- Ayurveda emphasizes gentle detoxification to remove toxins (Ama) from the body and support immune health. Herbal teas, digestive spices, and other detox practices can help clear toxins that may aggravate autoimmune responses.
- Lifestyle Adjustments
- Stress Management: Since stress can exacerbate autoimmune conditions, Ayurveda recommends practices like meditation, pranayama (breathwork), and yoga to calm the mind and reduce cortisol levels (Frawley, 2000).
- Daily Routine (Dinacharya): Consistent sleep, regular meal times, and balanced daily activities are recommended to stabilize immune function.
- Ayurvedic Topical Applications
- Soothing, natural applications such as aloe vera or rose water can help reduce irritation and inflammation in areas affected by blisters, providing gentle relief.
Conclusion
Pemphigus vulgaris and bullous pemphigoid are both vesiculobullous autoimmune skin disorders, yet they differ significantly in their underlying mechanisms, clinical presentation, and treatment approaches. A comprehensive understanding of these differences is essential for accurate diagnosis and effective management. While conventional treatments are necessary to control immune activity, an Ayurvedic approach can offer additional benefits by promoting immune balance and supporting skin health naturally.
Related-
Know More About Ayurveda Treatment For skin Dermatology.
GET IN TOUCH
Schedule a Visit
References
1.Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66(2):255–270. doi: 10.1007/s12026-018-8986-7. [DOI] [PubMed] [Google Scholar]
2.Daniel BS, Murrell DF. Review of autoimmune blistering diseases: the Pemphigoid diseases. J Eur Acad Dermatol Venereol. 2019;33(9):1685–1694. doi: 10.1111/jdv.15679. [DOI] [PubMed] [Google Scholar]
3.Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Arch Dermatol Res. 2015;307(4):291–298. doi: 10.1007/s00403-014-1531-1. [DOI] [PubMed] [Google Scholar]
4.Marazza G, Pham HC, Schärer L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol. 2009;161(4):861–868. doi: 10.1111/j.1365-2133.2009.09300.x. [DOI] [PubMed] [Google Scholar]
5.Bertram F, Bröcker EB, Zillikens D, et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7(5):434–440. doi: 10.1111/j.1610-0387.2008.06976.x. [DOI] [PubMed] [Google Scholar]
6.Baican A, Baican C, Chiriac G, et al. Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania. Int J Dermatol. 2010;49(7):768–774. doi: 10.1111/j.1365-4632.2009.04345.x. [DOI] [PubMed] [Google Scholar]
7.Pisanti S, Sharav Y, Kaufman E, Posner LN. Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol. 1974;38(3):382–387. doi: 10.1016/0030-4220(74)90365-X. [DOI] [PubMed] [Google Scholar]
8.Chams-Davatchi C, Valikhani M, Daneshpazhooh M, et al. Pemphigus: analysis of 1209 cases. Int J Dermatol. 2005;44:470–476. doi: 10.1111/j.1365-4632.2004.02501.x. [DOI] [PubMed] [Google Scholar]
9.Simon DG, Krutchkoff D, Kaslow RA, Zarbo R. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol. 1980;116(9):1035–1037. doi: 10.1001/archderm.1980.01640330073017. [DOI] [PubMed] [Google Scholar]
10.Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study. BMJ. 2008;337(7662):a180. doi: 10.1136/bmj.a180. [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol. 2011;131(3):637–643. doi: 10.1038/jid.2010.301. [DOI] [PubMed] [Google Scholar]
12.Ahmed AR, Yunis EJ, Khatri K, et al. Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci U S A. 1990;87(19):7658–7662. doi: 10.1073/pnas.87.19.7658. [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Ahmed AR, Wagner R, Khatri K, et al. Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci U S A. 1991;88(11):5056–5060. doi: 10.1073/pnas.88.11.5056. [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Sun Y, Liu H, Yang B, et al. Investigation of the predisposing factor of pemphigus and its clinical subtype through a genome-wide association and next generation sequence analysis. J Eur Acad Dermatol Venereol. 2019;33(2):410–415. doi: 10.1111/jdv.15227. [DOI] [PubMed] [Google Scholar]
15.Mahmoudi H, Ebrahimi E, Daneshpazhooh M, et al. Single-nucleotide polymorphisms associated with pemphigus vulgaris: potent markers for better treatment and personalized medicine. Int J Immunogenet. 2020;47(1):41–49. doi: 10.1111/iji.12451. [DOI] [PubMed] [Google Scholar]
16.Delgado JC, Turbay D, Yunis EJ, et al. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci U S A. 1996;93(16):8569–8571. doi: 10.1073/pnas.93.16.8569. [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Di Zenzo G, Amber KT, Sayar BS, Müller EJ, Borradori L. Immune response in pemphigus and beyond: progresses and emerging concepts. Semin Immunopathol. 2016;38(1):57–74. doi: 10.1007/s00281-015-0541-1. [DOI] [PubMed] [Google Scholar]
18.Takahashi H, Iriki H, Mukai M, et al. Autoimmunity and immunological tolerance in autoimmune bullous diseases. Int Immunol. 2019;31(7):431–437. doi: 10.1093/intimm/dxz030. [DOI] [PubMed] [Google Scholar]
19.Cho MJ, Ellebrecht CT, Hammers CM, et al. Determinants of VH1-46 cross-reactivity to pemphigus vulgaris autoantigen desmoglein 3 and rotavirus antigen VP6. J Immunol. 2016;197(4):1065–1073. doi: 10.4049/jimmunol.1600567. [DOI] [PMC free article] [PubMed] [Google Scholar]
20.Qian Y, Jeong JS, Ye J, et al. Overlapping IgG4 responses to self- and environmental antigens in endemic pemphigus foliaceus. J Immunol. 2016;196(5):2041–2050. doi: 10.4049/jimmunol.1502233. [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882–894. doi: 10.1016/S0140-6736(19)31778-7. [DOI] [PubMed] [Google Scholar]
22.Pollmann R, Schmidt T, Eming R, Hertl M. Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches. Clin Rev Allergy Immunol. 2018;54(1):1–25. doi: 10.1007/s12016-017-8662-z. [DOI] [PubMed] [Google Scholar]
23.Lo Schiavo A, Ruocco E, Brancaccio G, Caccavale S, Ruocco V, Wolf R. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clin Dermatol. 2013;31(4):391–399. doi: 10.1016/j.clindermatol.2013.01.006. [DOI] [PubMed] [Google Scholar]
24.Genovese G, Di Zenzo G, Cozzani E, Berti E, Cugno M, Marzano AV. New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol. 2019;10:1506. doi: 10.3389/fimmu.2019.01506. [DOI] [PMC free article] [PubMed] [Google Scholar]
